MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

By R. Garzon, Stefano Volinia, Chang-Gong Liu, Cecilia Fernandez-Cymering, T. Palumbo, F. Pichiorri, M. Fabbri, Kevin R. Coombes, H. Alder, Tatsuya Nakamura and 8 more. Blood, 2008

681 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c2d5d5fb19dc4fd19f6f448f0dc4c099a49dd050

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

microRNAs in cancer (2013, background): “miR-155 is overexpressed in aggressive CLL (68), pediatric Burkitt lymphoma (69), Hodgkin lymphoma (70), primary mediastinal non-Hodgkin lymphoma (70), acute myeloid leukemia (AML) (71), lung cancer (38), and breast cancer (72).”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “…miR-21 is a genuine oncogene. miR-17-92 cluster and miR-155, both discovered to be overexpressed in lymphoproliferative disorders, including lymphomas and leukaemia (Garzon et al, 2008; He et al, 2005), were the ﬁrst examples of miRNAs with oncogenic activity validated in engineered animal models.”
Reprogramming of miRNA networks in cancer and leukemia. (2010, neutral): “…(Visone et al. 2009), E-TABM-508 (Pichiorri et al. 2008) , E-TABM-429 (Garzon et al. 2008a), E-TABM-434 (Petrocca et al. 2008), E-TABM-405 (Garzon et al. 2008b), E-TABM-343 (Iorio et al. 2007), E-TABM-41 and E-TABM-42 (Calin et al. 2005), E-TABM-48 (Roldo et al. 2006), E-TABM-22…”
MicroRNAs in development and disease. (2011, background): “Additionally, a separate miRNA profiling revealed that AML patients with higher levels of miR-191 and miR199a had a lower event-free survival rate (201).”
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype (2010, background): “Discussion There is accumulating evidence that miRNA expression is dysregulated in various cancers, including hematological malignancie”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, neutral): “Moreover, specific miRNA-expression signatures have been associated with specific translocations in hematopoietic malignancies”